000163452 001__ 163452
000163452 005__ 20240321115501.0
000163452 0247_ $$2pmc$$apmc:PMC9213601
000163452 0247_ $$2doi$$a10.1007/s11357-021-00497-w
000163452 0247_ $$2pmid$$apmid:34940948
000163452 0247_ $$2ISSN$$a2509-2715
000163452 0247_ $$2ISSN$$a0161-9152
000163452 0247_ $$2ISSN$$a1574-4647
000163452 0247_ $$2ISSN$$a2331-3765
000163452 0247_ $$2ISSN$$a2452-0756
000163452 0247_ $$2ISSN$$a2509-2723
000163452 0247_ $$2altmetric$$aaltmetric:119703410
000163452 0247_ $$2ISSN$$a2152-4041
000163452 0247_ $$2ISSN$$a2331-3773
000163452 037__ $$aDZNE-2022-00212
000163452 041__ $$aEnglish
000163452 082__ $$a610
000163452 1001_ $$0P:(DE-2719)2810394$$aKilimann, Ingo$$b0$$eFirst author$$udzne
000163452 245__ $$aInverse association between the anticholinergic burden and hippocampus volume in a population-based cohort across the entire adult age range.
000163452 260__ $$a[Cham]$$bSpringer International Publishing$$c2022
000163452 3367_ $$2DRIVER$$aarticle
000163452 3367_ $$2DataCite$$aOutput Types/Journal article
000163452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710944025_2066
000163452 3367_ $$2BibTeX$$aARTICLE
000163452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163452 3367_ $$00$$2EndNote$$aJournal Article
000163452 500__ $$a(CC BY)
000163452 520__ $$aMany medications of different indications have a relevant anticholinergic activity. The anticholinergic burden of medication has been shown to have significant effects on the cognition and the risk for cognitive impairment and dementia particularly in older patients. So far, most of the studies used data from geriatric patients and the effect of the anticholinergic burden on brain structures is still unexplored. Our study aimed to analyze possible associations of hippocampus and cholinergic basal forebrain volumes as vulnerable brain structures for the development of dementia and the anticholinergic burden in a population-based cohort of non-demented participants spanning the adult age range from 21 to 80 years. We analyzed associations between medication-related anticholinergic burden and structural MRI volumes from participants (n = 3087, 52.2% female) of the population-based 'Study of Health in Pomerania' (SHIP). Anticholinergic burden was obtained from the current medication plan using the Anticholinergic Burden Scale (ACB). All analyses were adjusted for age, sex, education, and total intracranial volume. We found statistically significant associations between the ACB and the left and right hippocampus volume but not for the basal forebrain cholinergic system. Complementary voxel-based analysis across all participants revealed FWE-corrected (p = < 0.05) clusters in the temporo-parietal regions reaching into frontal areas, showing reduced volumes with higher ACB scores. We identified an association between anticholinergic burden of medication on hippocampal volume suggesting a potential inverse effect of such medication. This association highlights the importance of a careful prescription of medication with anticholinergic activity at any adult age.
000163452 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163452 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163452 650_7 $$2Other$$aAlzheimer’s disease
000163452 650_7 $$2Other$$aCognitive impairment
000163452 650_7 $$2Other$$aHippocampus
000163452 650_7 $$2Other$$aMedication
000163452 650_2 $$2MeSH$$aAged
000163452 650_2 $$2MeSH$$aAged, 80 and over
000163452 650_2 $$2MeSH$$aCholinergic Agents: therapeutic use
000163452 650_2 $$2MeSH$$aCholinergic Antagonists: adverse effects
000163452 650_2 $$2MeSH$$aCognitive Dysfunction: chemically induced
000163452 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000163452 650_2 $$2MeSH$$aCognitive Dysfunction: drug therapy
000163452 650_2 $$2MeSH$$aDementia
000163452 650_2 $$2MeSH$$aFemale
000163452 650_2 $$2MeSH$$aHippocampus: diagnostic imaging
000163452 650_2 $$2MeSH$$aHumans
000163452 650_2 $$2MeSH$$aMale
000163452 7001_ $$0P:(DE-2719)2810631$$aWucherer, Diana$$b1$$udzne
000163452 7001_ $$aIttermann, Till$$b2
000163452 7001_ $$aVölzke, Henry$$b3
000163452 7001_ $$aBülow, Robin$$b4
000163452 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b5$$udzne
000163452 7001_ $$0P:(DE-2719)2811781$$aGrabe, Hans Jörgen$$b6$$udzne
000163452 7001_ $$0P:(DE-2719)2810491$$aWittfeld, Katharina$$b7$$udzne
000163452 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan Johannes$$b8$$eLast author$$udzne
000163452 773__ $$0PERI:(DE-600)2886418-9$$a10.1007/s11357-021-00497-w$$n3$$p1715-1726$$tGeroScience$$v44$$x2509-2723$$y2022
000163452 8564_ $$uhttps://pub.dzne.de/record/163452/files/DZNE-2022-00212.pdf$$yOpenAccess
000163452 909CO $$ooai:pub.dzne.de:163452$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810394$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811781$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810491$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000163452 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000163452 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163452 9141_ $$y2022
000163452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000163452 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGEROSCIENCE : 2021$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000163452 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-05-04$$wger
000163452 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163452 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bGEROSCIENCE : 2021$$d2022-11-17
000163452 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000163452 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000163452 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000163452 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000163452 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x1
000163452 9201_ $$0I:(DE-2719)5000001$$kAG Grabe$$lBiomarkers of Dementia in the General Population$$x2
000163452 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x3
000163452 980__ $$ajournal
000163452 980__ $$aVDB
000163452 980__ $$aI:(DE-2719)1510100
000163452 980__ $$aI:(DE-2719)1510800
000163452 980__ $$aI:(DE-2719)5000001
000163452 980__ $$aI:(DE-2719)1510600
000163452 980__ $$aUNRESTRICTED
000163452 9801_ $$aFullTexts